Member Info for EmeraldCarrots

So was the 2m trade a director buy last Friday? Very late in the day. RNS any time now???

Good vibes.

In case u misssed it!>>

Christmas lift for Genedrive, up 6.6%, or 0.15p, at 2.43p, as the pharmacogenetic tester revealed good results for it's CYP2C19-ID stroke kit. The AIM-listed firm said that in a 202 patient study ther point-of-care kit outperformed lab testing in speed, accuracy, and rate of test failure. The kit is recommmended for use by the NHS in prescribing clopidogrel for isachaemic attacks, as 30% of patients have a genetic resistance.".

Spike to 3p ish Monday then?

All IMHO.

johnlay****

"...tomorrow at 7am to see if there is a rns re that 2m buy late on friday.".

=========================

yes. very interesting. 2,000,000 @ 2.45p on friday. if it was a director then there will be an rns to say so. before 9:30 am i'd say.

the agm is at 10 am too, so maybe more news. the directors need to be quizzed about the fda application. it is most important. the potential revenue in the usa eclipses the whole of the nhs easily.

all imho.

In case u misssed it!>>

Christmas lift for Genedrive, up 6.6%, or 0.15p, at 2.43p, as the pharmacogenetic tester revealed good results for it's CYP2C19-ID stroke kit. The AIM-listed firm said that in a 202 patient study ther point-of-care kit outperformed lab testing in speed, accuracy, and rate of test failure. The kit is recommmended for use by the NHS in prescribing clopidogrel for isachaemic attacks, as 30% of patients have a genetic resistance.".

Spike to 3p ish Monday then?

All IMHO.

You crack me up! Hilarious! Worried about Monday after the Daily Mail article?????? Vey sad person.

Christmas lift for Genedrive, up 6.6%, or 0.15p, at 2.43p, as the pharmacogenetic tester revealed good results for it's CYP2C19-ID stroke kit. The AIM-listed firm said that in a 202 patient study ther point-of-care kit outperformed lab testing in speed, accuracy, and rate of test failure. The kit is recommmended for use by the NHS in prescribing clopidogrel for isachaemic attacks, as 30% of patients have a genetic resistance.".

Spike to 3p ish Monday then?

All IMHO.

Https://www.jmdjournal.org/article/S1525-1578(24)00312-X/fulltext

"Conclusion

This validation study demonstrates the Genedrive CYP2C19 ID kit to have a high diagnostic accuracy for clinically relevant CYP2C19 variation. The platform had a superior performance to the reference test, with a higher accuracy and lower failure rate. Implementation of the Genedrive CYP2C19 ID Kit in clinical practice could provide an accurate, rapid, cost-effective and non-invasive alternative to standard laboratory testing and ensures results are available in a clinically relevant format and timeframe to guide patient care.".

The months go by and not much is known.

The "Breakthrough Device Designation from the U.S. FDA" RNS was back on 15th July !!!!!!!!!!!!!!!!!!!!!!!!

Maybe closer than we think??????

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

- OVER 5 MONTHS AGO !!!!!!!!!!!!!!!!!!!!!!!!

Someone at the AGM needs to ask where we are with the FDA application. It's far more important than the NHS roll outs. What has happened in the last FIVE MONTHS????????????????

The months go by and not much is known.

The "Breakthrough Device Designation from the U.S. FDA" RNS was back on 15th July !!!!!!!!!!!!!!!!!!!!!!!!

Maybe closer than we think??????

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Flobble.

Flibble.

They bring nothing to this board.

The likes of Illumina, Thermo Fisher, Astrazeneca and Eisai must keep a very close eye on Angle Plc. They simply must want to know where Angle are on a weekly basis. No brainer. The sp here is like a ticking time bomb. IMHO 32p a share will be seen as silly low in time.

All IMHO.

People's minds I expect! See chart.

All IMHO.

Forward too here folks!! It does not get better than that.

Have a feeling 2025 will be the year for Gendrive. Sp likely to ROCKET!!!!!!!!!!!

All IMHO.

Liamcossie.

"I believe a bigger contract again will come off the back of this, not to mention new contracts to I bet are already being discussed, IMO ofcourse!".

==================================

I am surprised that Angle have not landed more contracts. Very surprised. I suspect Mr Newland drives a hard bargain (too hard?) knowing Angle's Parsortix system is streets ahead of the competition and one not so good contract could set a precedent. The evidence mounts about Angle's parsortix machine and it's abitity to catch LIVE circulating tumour cells from a standard blood sample.

All IMHO.

Significant. On 2nd Jan it will have been a year since. Eisai contracted Angle Plc to monitor about 140 participants HER2 levels during a real cancer drug trial. The drug in question was designed to target HER2 positive cancer tumour. Clearly Eisai wants to monitor the participants cancer as sometimes over weeks or months a cancer can change its HER2 status. Say from HER2 positive to HER2 negative in which case their expensive drug would not work, being designed to lock on to HER2 positive tumours. The results could be TRANSFORMATIONAL for Angle Plc. That is why the sp zooned up to 32p in Jan last year from just 12p..... See Chart.

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

All IMHO.

On Monday>>>>>>

https://www.lse.co.uk/rns/GDR/posting-of-annual-report-and-notice-of-agm-6d1xukig1mkzj4e.html

RNS this moring:-

https://www.lse.co.uk/rns/GDR/genedrive174-cyp2c19-id-kit-performance-published-5xkw7p2896a4284.html

BeardedDragon

Incorrect information by you and you know it. The share buys were in the open market at varous prices. People like you should be banned.